Imagine having a means to understand what’s happening in a person’s cancer situation without needing an invasive procedure – just a simple blood test.
This isn’t a fragment from a science fiction story, but a tangible reality emerging from a study about lung cancer, which continues to be a leading cause of cancer deaths worldwide.
Understanding Lung Cancer: A Brief Overview
Lung cancer primarily starts in the lungs and can eventually spread to other parts of the body. The most common type, Non-Small Cell Lung Cancer (NSCLC), takes a massive share of 84% of all lung cancer cases.
The severity and spread of cancer are traditionally determined through tumor tissue biopsy – which essentially means taking a small piece of the tumor through surgical means to examine it.
While this has been the gold standard, it comes with its set of challenges, mainly being invasive and only providing a snapshot of the cancer from a single location.
Now, a breakthrough presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting reveals a new way of peering into the spread and severity of lung cancer, but with a less intrusive approach.
The Breakthrough: What’s a Liquid Biopsy?
In the realm of medical science, a ‘liquid biopsy’ is making waves as it possesses the potential to unlock comprehensive data about the cancer that resides within the body, all through a simple blood test.
Think of this as a non-invasive detective that can tell doctors about the cancer’s whereabouts and how much it has spread.
Dr. Aadel Chaudhuri from the Siteman Cancer Center of Washington University and his team have been working on this test to help make crucial decisions about lung cancer treatment.
Simply put, the test helps understand whether the cancer is still localized or has spread to a level that’s not easily visible.
This information is vital because it helps doctors decide what form of treatment would work best – focused high-dose radiation or drug-based therapy.
In the case of NSCLC, it has been noticed that some patients, where the cancer spread was limited (termed as oligometastatic), responded well and lived longer periods without cancer after receiving high-dose radiation. The challenge was identifying who these patients were.
Real-world Impact: The Study and Its Promising Outcomes
Between 2016 and 2022, the research team dove into the data from 309 patients who had this specific type of lung cancer (oligometastatic NSCLC).
They specifically looked at patients who had undergone this special blood test before receiving radiation therapy.
The findings were promising and a bit surprising.
Those who showed no signs of circulating tumor DNA (ctDNA – tiny pieces of DNA from the cancer cells that circulate in the blood) before the treatment lived considerably longer (about 25 months) than those who had detectable ctDNA (around 16.8 months).
This was similar to how long they lived without the cancer coming back – 8.8 months for those with no ctDNA and 5.4 months for those with ctDNA.
In essence, this simple blood test offered a glimpse into the future trajectory of the patient’s cancer situation, helping doctors to personalize the treatment accordingly.
Dr. Chaudhuri articulated, “When you have a detectable ctDNA level, you have a higher burden of disease.”
This means, by knowing the ctDNA level through this liquid biopsy, they can decide the best course of action in treatment, potentially offering a lifeline where there wasn’t one.
This research acts as a beacon of optimism for many healthcare practitioners and patients alike.
The possibility of non-invasively assessing a patient and determining the best course of treatment not only personalizes medicine to an unprecedented level but also aids in avoiding unnecessary treatments, thereby offering a better quality of life for those navigating through the hurdles of cancer.
In conclusion, as we anticipate further advancements in this field, the liquid biopsy shines as a triumphant progression, signaling a future where the intricacies of cancer are not hidden behind a veil, enabling informed decisions that pave the way towards recovery, remission, and possibly, a cure.
If you care about medicine, please read studies that vitamin D could help lower the risk of autoimmune diseases, and drug for inflammation may stop spread of cancer.
For more information about medicine, please see recent studies about which drug can harm your liver most, and results showing this drug can give your immune system a double boost against cancer.
The research findings can be found in npj Precision Oncology.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
